<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03269474</url>
  </required_header>
  <id_info>
    <org_study_id>41142</org_study_id>
    <nct_id>NCT03269474</nct_id>
  </id_info>
  <brief_title>Computational Drug Repurposing for EBS</brief_title>
  <official_title>Computational Drug Repurposing for Epidermolysis Bullosa Simplex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joyce Teng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare gene expression differences between blistered and non-blistered skin
      from individuals with EBS, as well as normal skin from non-EBS subjects. State of the art
      computational analysis will be performed to help identify new drugs that might help EBS wound
      healing and reduce pain. Researchers will focus on drugs that have already been approved for
      treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for
      treatment of EBS. Drug development is a very expensive process taking decades for execution.
      Drug repurposing on the other hand, significantly reduces the cost and shortens the amount of
      time that is needed to bring effective treatments to clinical use. To date, there is no
      specific treatment targeting the physiology and immunologic response in EB patients during
      wound healing. Market availability of repurposed medications will provide EBS patients rapid
      access to treatments, thus improving their quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although gene, cell, and protein-based therapies are in development for patients suffering
      from epidermolysis bullosa simplex (EBS), new pharmacological treatments are in dire need.
      Characterizing molecular changes in EBS, including gene expression, can identify new
      therapeutic targets and drugs that modulate those targets. However, sifting through gene
      expression information to identify the most promising drug targets is a complex data
      challenge. The goal of the study will identify a computational approach to evaluate and
      identify existing drugs approved for other diseases that can be repurposed for EBS patients.
      The study will perform an unprecedented characterization of gene expression changes in EBS
      patients compared to healthy, non-EBS individuals across multiple tissues. Using a validated
      computational drug discovery platform, researchers will analyze gene expression and drug data
      using unique algorithms. In the first year, a list of ten, safety drugs more probable to
      treat the EBS disease state will be identified. The most promising drugs discovered will then
      be tested in the clinic setting.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize gene expression changes in EBS using RNA sequencing (RNA-seq) and Computational Profiling Potential Drug Targets</measure>
    <time_frame>Through the completion of study in 1 year.</time_frame>
    <description>Using bioinformatic algorithms to identify changes in gene expression and review of over 2000 FDA-approved drugs based on predicted modulation of gene expression changes using a computational evolutionary algorithm system.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Epidermolysis Bullosa Simplex</condition>
  <condition>Healthy</condition>
  <condition>Genetic Skin Disease</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <description>Blood and tissue specimen will be collected from subjects with an EBS diagnosis. Tissue specimen will be collected from blistered and nonblistered skin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Blood and tissue specimen will be collected from healthy subjects with non-EBS. Tissue specimen will be collected from an inconspicuous skin area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Experimental Group</intervention_name>
    <description>Subjects with EBS diagnosis</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Punch biopsies of non-blistering and blistering skin, and peripheral blood mononuclear cells
      (PBMCs): CD8+ cytotoxic T cells and CD4+ helper T cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subject of all ages with either 1) a diagnosis of EBS subjects or 2) healthy, non-EBS
        subjects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of all ages

          -  Diagnosis of EBS subjects

          -  Healthy, non-EBS subjects

          -  Ability to complete study visit to collect tissue and blood specimen

        Exclusion Criteria:

          -  Pregnancy, breast feeding

          -  Prior history of liver disease

          -  Serious known concurrent medical illness or infection, which could potentially present
             a safety risk and/or prevent tissue collection from subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce M Teng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Dermatology Clinic at Stanford Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McLaren PJ, Mayne M, Rosser S, Moffatt T, Becker KG, Plummer FA, Fowke KR. Antigen-specific gene expression profiles of peripheral blood mononuclear cells do not reflect those of T-lymphocyte subsets. Clin Diagn Lab Immunol. 2004 Sep;11(5):977-82.</citation>
    <PMID>15358662</PMID>
  </reference>
  <reference>
    <citation>Sleasman JW, Leon BH, Aleixo LF, Rojas M, Goodenow MM. Immunomagnetic selection of purified monocyte and lymphocyte populations from peripheral blood mononuclear cells following cryopreservation. Clin Diagn Lab Immunol. 1997 Nov;4(6):653-8.</citation>
    <PMID>9384284</PMID>
  </reference>
  <reference>
    <citation>Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016 May;34(5):525-7. doi: 10.1038/nbt.3519. Epub 2016 Apr 4. Erratum in: Nat Biotechnol. 2016 Aug 9;34(8):888.</citation>
    <PMID>27043002</PMID>
  </reference>
  <reference>
    <citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010 Jan 1;26(1):139-40. doi: 10.1093/bioinformatics/btp616. Epub 2009 Nov 11.</citation>
    <PMID>19910308</PMID>
  </reference>
  <reference>
    <citation>Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014 Jan;42(Database issue):D1091-7. doi: 10.1093/nar/gkt1068. Epub 2013 Nov 6.</citation>
    <PMID>24203711</PMID>
  </reference>
  <reference>
    <citation>Sugaya N, Kanai S, Furuya T. Dr. PIAS 2.0: an update of a database of predicted druggable protein-protein interactions. Database (Oxford). 2012 Oct 10;2012:bas034. doi: 10.1093/database/bas034. Print 2012.</citation>
    <PMID>23060433</PMID>
  </reference>
  <reference>
    <citation>Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007 Dec 1;23(23):3251-3. Epub 2007 Jul 20.</citation>
    <PMID>17644558</PMID>
  </reference>
  <results_reference>
    <citation>Cohn HI, Teng JM. Advancement in management of epidermolysis bullosa. Curr Opin Pediatr. 2016 Aug;28(4):507-16. doi: 10.1097/MOP.0000000000000380. Review.</citation>
    <PMID>27386970</PMID>
  </results_reference>
  <results_reference>
    <citation>Uitto J, Bruckner-Tuderman L, Christiano AM, McGrath JA, Has C, South AP, Kopelan B, Robinson EC. Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015. J Invest Dermatol. 2016 Feb;136(2):352-8. doi: 10.1016/j.jid.2015.10.050. Review.</citation>
    <PMID>26802230</PMID>
  </results_reference>
  <results_reference>
    <citation>Nyström A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, Bruckner-Tuderman L. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med. 2015 Sep;7(9):1211-28. doi: 10.15252/emmm.201505061.</citation>
    <PMID>26194911</PMID>
  </results_reference>
  <results_reference>
    <citation>Wally V, Kitzmueller S, Lagler F, Moder A, Hitzl W, Wolkersdorfer M, Hofbauer P, Felder TK, Dornauer M, Diem A, Eiler N, Bauer JW. Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study. Orphanet J Rare Dis. 2013 May 7;8:69. doi: 10.1186/1750-1172-8-69.</citation>
    <PMID>23651789</PMID>
  </results_reference>
  <results_reference>
    <citation>Li J, Zheng S, Chen B, Butte AJ, Swamidass SJ, Lu Z. A survey of current trends in computational drug repositioning. Brief Bioinform. 2016 Jan;17(1):2-12. doi: 10.1093/bib/bbv020. Epub 2015 Mar 31. Review.</citation>
    <PMID>25832646</PMID>
  </results_reference>
  <results_reference>
    <citation>Low YS, Daugherty AC, Schroeder EA, Chen W, Seto T, Weber S, Lim M, Hastie T, Mathur M, Desai M, Farrington C, Radin AA, Sirota M, Kenkare P, Thompson CA, Yu PP, Gomez SL, Sledge GW Jr, Kurian AW, Shah NH. Synergistic drug combinations from electronic health records and gene expression. J Am Med Inform Assoc. 2017 May 1;24(3):565-576. doi: 10.1093/jamia/ocw161.</citation>
    <PMID>27940607</PMID>
  </results_reference>
  <results_reference>
    <citation>Bchetnia M, Tremblay ML, Leclerc G, Dupérée A, Powell J, McCuaig C, Morin C, Legendre-Guillemin V, Laprise C. Expression signature of epidermolysis bullosa simplex. Hum Genet. 2012 Mar;131(3):393-406. doi: 10.1007/s00439-011-1077-7. Epub 2011 Aug 30.</citation>
    <PMID>21877134</PMID>
  </results_reference>
  <results_reference>
    <citation>Roth W, Reuter U, Wohlenberg C, Bruckner-Tuderman L, Magin TM. Cytokines as genetic modifiers in K5-/- mice and in human epidermolysis bullosa simplex. Hum Mutat. 2009 May;30(5):832-41. doi: 10.1002/humu.20981.</citation>
    <PMID>19267394</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee B, Geyfman M, Andersen B, Dai X. Analysis of gene expression in skin using laser capture microdissection. Methods Mol Biol. 2013;989:109-17. doi: 10.1007/978-1-62703-330-5_10.</citation>
    <PMID>23483391</PMID>
  </results_reference>
  <results_reference>
    <citation>Løvendorf MB, Mitsui H, Zibert JR, Røpke MA, Hafner M, Dyring-Andersen B, Bonefeld CM, Krueger JG, Skov L. Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis. Exp Dermatol. 2015 Mar;24(3):187-93. doi: 10.1111/exd.12604.</citation>
    <PMID>25431026</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Joyce Teng</investigator_full_name>
    <investigator_title>Director of Pediatric Dermatology</investigator_title>
  </responsible_party>
  <keyword>epidermolysis bullosa simplex</keyword>
  <keyword>genetic expression</keyword>
  <keyword>drug repurposing</keyword>
  <keyword>computational approaches</keyword>
  <keyword>drug discovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Simplex</mesh_term>
    <mesh_term>Skin Diseases, Genetic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>As of now, there are no plans to share the data with other researchers. Once the outcome measures have been accomplished, the research team will publish results for the entire clinicaltrials.gov community and researchers for this vulnerable population study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

